サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1798895

遺伝子がんバイオマーカーの世界市場

Genetic Cancer Biomarkers

出版日
ページ情報
英文 276 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.28円
遺伝子がんバイオマーカーの世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 276 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

遺伝子がんバイオマーカーの世界市場は2030年までに139億米ドルに達する

2024年に52億米ドルと推定される遺伝子がんバイオマーカーの世界市場は、2024年から2030年にかけてCAGR 17.6%で成長し、2030年には139億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるOMICSは、CAGR 15.5%を記録し、分析期間終了時には66億米ドルに達すると予測されます。バイオインフォマティクス分野の成長率は、分析期間でCAGR 20.2%と推定されます。

米国市場は14億米ドル、中国はCAGR22.9%で成長予測

米国の遺伝子がんバイオマーカー市場は、2024年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに30億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは22.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.3％と15.7％と予測されています。欧州では、ドイツがCAGR約14.0%で成長すると予測されています。

世界の遺伝子がんバイオマーカー市場- 主要動向と促進要因のまとめ

がんの診断と治療において遺伝子バイオマーカーが重要性を増しているのはなぜか？

遺伝子がんバイオマーカーは、腫瘍の存在、進行、治療反応性を明らかにするDNAまたはRNAベースの指標です。これらのバイオマーカーは早期発見、予後評価、治療法の選択、再発モニタリングに用いられます。がん研究が個別化治療戦略に向けて発展するにつれ、遺伝子バイオマーカーは個々の腫瘍プロファイルに治療法を適合させる上で不可欠な役割を果たします。このアプローチは薬剤投与における試行錯誤を減らし、治療成績を向上させる。

その応用範囲は、先天的ながんリスクの同定から腫瘍内の後天的変異の検出まで多岐にわたる。BRCA1/2、EGFR、KRAS、BRAFのようなバイオマーカーは、乳がん、肺がん、大腸がん、黒色腫の症例における治療決定の指針となります。リキッドバイオプシーを含む非侵襲的サンプリング技術は遺伝子検査へのアクセスを改善し、より頻繁なモニタリングを可能にしています。がん専門医によるコンパニオン診断の採用が増加しており、臨床診療における遺伝子バイオマーカーの役割がさらに確立されつつあります。

技術の進歩はバイオマーカーの検出と解釈をどのように強化しているか？

次世代シーケンシング（NGS）やデジタルPCRなどのハイスループットシーケンス技術により、がん関連変異のより迅速かつ正確な同定が可能になっています。これらのツールは、少量のサンプルや劣化したサンプルからでさえ、高感度で複数の遺伝子の同時解析を可能にします。計算プラットフォームは現在、バリアントコーリング、変異アノテーション、予測分析をサポートし、バイオマーカーの解釈と臨床的意思決定を改善しています。

人工知能と機械学習の統合により、大規模な患者コホート全体のゲノムパターンを分析することで、バイオマーカー分類が洗練されつつあります。クラウドベースのプラットフォームにより、匿名化されたゲノムデータの共有が可能となり、研究開発や治療法開発に利用されています。ラボで開発された検査やFDA承認のパネルにより、固形がんや血液悪性腫瘍に対する実用的なバイオマーカーの範囲が拡大しています。分子診断学が進化し続ける中、バイオインフォマティクスとデータ統合は、複雑化するがんゲノミクスの管理に不可欠なものとなりつつあります。

がん領域で遺伝子バイオマーカーが最も広く採用されているのはどこですか？

病院、がんセンター、基準検査室が、遺伝子がんバイオマーカー検査の主要ユーザーです。高所得国では、バイオマーカー検査は、非小細胞肺がん、大腸がん、乳がんなど、いくつかのがんの標準治療経路に組み込まれています。検査は、治療適格性の評価、耐性の予測、微小残存病変のモニタリングに用いられています。新興市場の腫瘍内科診療所も、診断ラボや製薬会社との提携を通じてバイオマーカー検査を導入しています。

バイオ製薬企業は、特に免疫療法や標的療法などの臨床試験において、患者の層別化にバイオマーカーを利用しています。プレシジョン・オンコロジー・プログラムやがん登録では、遺伝子プロファイリングを用いて変異の有病率や治療成績を追跡しています。NGSプラットフォームと遺伝カウンセリングへのアクセスが改善されるにつれて、地域の腫瘍診療所では日常的なワークフローにバイオマーカー検査が組み込まれつつあります。がん医療における学術的、商業的な両分野で採用が拡大しています。

遺伝子がんバイオマーカー市場の成長の原動力は？

遺伝子がんバイオマーカー市場の成長は、分子診断の統合、治療の個別化、シーケンスの利用しやすさに関連するいくつかの要因によってもたらされます。がん治療におけるバイオマーカー誘導治療の増加は、包括的な変異パネルとコンパニオン診断の需要を支えています。NGS、リキッドバイオプシー、デジタルPCRの進歩により、より迅速、低侵襲、高感度の変異検出が可能になっています。バイオマーカー同定を必要とする標的薬の開発、腫瘍学に焦点を当てた臨床試験の拡大、遺伝子検査に対する償還の進展も成長を支えています。精密医療ががん医療を変革し続ける中、遺伝子バイオマーカーは診断の革新と治療の調整において中心的な役割を担っています。

セグメント

テクノロジー（OMICS、バイオインフォマティクス、その他のテクノロジー）、がん種（乳がん、前立腺がん、白血病、その他のがん種）

調査対象企業の例

  • Abbott Laboratories
  • Agilent Technologies
  • Amgen Inc.
  • Bio-Rad Laboratories
  • Bio-Techne Corporation
  • BGI Genomics
  • Caris Life Sciences
  • Danaher Corporation（Cepheid, Beckman Coulter）
  • Exact Sciences Corporation
  • Foundation Medicine（Roche）
  • Fulgent Genetics
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Veracyte, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38877

Global Genetic Cancer Biomarkers Market to Reach US$13.9 Billion by 2030

The global market for Genetic Cancer Biomarkers estimated at US$5.2 Billion in the year 2024, is expected to reach US$13.9 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2024-2030. OMICS, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Bioinformatics segment is estimated at 20.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 22.9% CAGR

The Genetic Cancer Biomarkers market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2030 trailing a CAGR of 22.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.3% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.0% CAGR.

Global Genetic Cancer Biomarkers Market - Key Trends & Drivers Summarized

Why Are Genetic Biomarkers Gaining Importance in Cancer Diagnosis and Treatment?

Genetic cancer biomarkers are DNA or RNA-based indicators that reveal the presence, progression, or treatment responsiveness of tumors. These biomarkers are used for early detection, prognosis evaluation, therapy selection, and recurrence monitoring. As cancer research evolves toward personalized treatment strategies, genetic biomarkers play an essential role in matching therapies to individual tumor profiles. This approach reduces trial-and-error in drug administration and improves treatment outcomes.

Applications range from identifying inherited cancer risk to detecting acquired mutations within tumors. Biomarkers such as BRCA1/2, EGFR, KRAS, and BRAF help guide therapeutic decisions in breast, lung, colorectal, and melanoma cases. Non-invasive sampling techniques, including liquid biopsies, are improving the accessibility of genetic testing, enabling more frequent monitoring. The growing adoption of companion diagnostics by oncology specialists is further establishing the role of genetic biomarkers in clinical practice.

How Are Technological Advances Enhancing Biomarker Detection and Interpretation?

High-throughput sequencing technologies such as next-generation sequencing (NGS) and digital PCR are enabling faster, more accurate identification of cancer-associated mutations. These tools allow simultaneous analysis of multiple genes with high sensitivity, even from small or degraded samples. Computational platforms now support variant calling, mutation annotation, and predictive analytics, improving biomarker interpretation and clinical decision-making.

Integration of artificial intelligence and machine learning is refining biomarker classification by analyzing genomic patterns across large patient cohorts. Cloud-based platforms enable sharing of anonymized genomic data for research and therapeutic development. Laboratory-developed tests and FDA-approved panels are expanding the range of actionable biomarkers for solid tumors and hematologic malignancies. As molecular diagnostics continue to evolve, bioinformatics and data integration are becoming essential to managing the increasing complexity of cancer genomics.

Where Are Genetic Biomarkers Being Adopted Most Widely in Oncology?

Hospitals, cancer centers, and reference laboratories are the primary users of genetic cancer biomarker testing. In high-income countries, biomarker testing is integrated into standard care pathways for several cancers, including non-small cell lung cancer, colorectal cancer, and breast cancer. Testing is used to assess therapy eligibility, predict resistance, and monitor minimal residual disease. Oncology practices in emerging markets are also adopting biomarker testing through partnerships with diagnostic labs and pharmaceutical companies.

Biopharmaceutical firms rely on biomarkers for patient stratification in clinical trials, especially for immunotherapy and targeted therapies. Precision oncology programs and cancer registries use genetic profiling to track mutation prevalence and treatment outcomes. As access to NGS platforms and genetic counseling improves, community oncology practices are incorporating biomarker testing into routine workflows. Adoption is growing across both academic and commercial segments of cancer care.

What Is Driving Growth in the Genetic Cancer Biomarkers Market?

Growth in the genetic cancer biomarkers market is driven by several factors related to molecular diagnostics integration, therapy personalization, and sequencing accessibility. Increased use of biomarker-guided treatment in oncology care is supporting demand for comprehensive mutation panels and companion diagnostics. Advances in NGS, liquid biopsy, and digital PCR are enabling faster, minimally invasive, and highly sensitive mutation detection. Growth is also supported by the development of targeted drugs that require biomarker identification, expansion of oncology-focused clinical trials, and reimbursement progress for genetic testing. As precision medicine continues to transform cancer care, genetic biomarkers are central to diagnostic innovation and therapeutic alignment.

SCOPE OF STUDY:

The report analyzes the Genetic Cancer Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (OMICS, Bioinformatics, Other Technologies); Cancer Type (Breast Cancer, Prostate Cancer, Leukemia, Other Cancer Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Abbott Laboratories
  • Agilent Technologies
  • Amgen Inc.
  • Bio-Rad Laboratories
  • Bio-Techne Corporation
  • BGI Genomics
  • Caris Life Sciences
  • Danaher Corporation (Cepheid, Beckman Coulter)
  • Exact Sciences Corporation
  • Foundation Medicine (Roche)
  • Fulgent Genetics
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Veracyte, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Genetic Cancer Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Personalized and Precision Oncology Drives Adoption of Genetic Biomarkers for Cancer Diagnosis and Treatment Selection
    • Advancements in Next-Generation Sequencing (NGS) and Genomic Profiling Enable High-Throughput Identification of Cancer-Associated Mutations
    • Increased Use of Companion Diagnostics With Targeted Therapies Strengthens Clinical Utility of Genetic Biomarkers
    • Growing Pipeline of Biomarker-Driven Immunotherapies Promotes Demand for Predictive and Prognostic Genetic Testing
    • Integration of Liquid Biopsy Technologies Enhances Early Detection and Monitoring Through Circulating Tumor DNA (ctDNA) Biomarkers
    • Regulatory Approvals and Reimbursement Support for Genomic Testing Boost Market Adoption in Clinical Oncology
    • Rising Incidence of Cancer Globally Expands Screening Programs and Biomarker-Based Risk Stratification Approaches
    • Partnerships Between Biotech Companies and Diagnostic Labs Accelerate Development of Multi-Gene Panels for Tumor Profiling
    • Expansion of Cancer Genomic Databases and AI-Powered Bioinformatics Platforms Enhances Biomarker Discovery and Interpretation
    • Growing Application of Pharmacogenomics in Cancer Treatment Planning Supports Demand for Germline and Somatic Mutation Analysis
    • Increased Role of Biomarkers in Monitoring Minimal Residual Disease (MRD) Strengthens Use Cases Beyond Initial Diagnosis
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Genetic Cancer Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Genetic Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for OMICS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for OMICS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for OMICS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Bioinformatics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • JAPAN
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • CHINA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • EUROPE
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Genetic Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • FRANCE
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • GERMANY
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • INDIA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Genetic Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Genetic Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • AFRICA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030

IV. COMPETITION